Barrett’s esophagus is a condition often resulting from reflux, characterized by stomach acid damaging the esophagus lining and causing cell changes. While these cells aren’t initially cancerous, there’s a risk they might transform into esophageal cancer, a type where cells in the esophagus proliferate uncontrollably, potentially spreading to other body parts. Esophageal cancer is among the deadliest cancers in adults, and early detection significantly improves survival rates compared to a diagnosis at an advanced stage. Since the symptoms of esophageal cancer can mimic heartburn and reflux, conducting early tests for cancer detection is crucial. Now, a non-endoscopic capsule sponge device has been designed to collect pan-esophageal samples which are then sent for laboratory testing to detect esophageal pre-cancer and other conditions. Cyted’s (Cambridge, UK) EndoSign cell collection device is designed to detect and monitor conditions such as chronic reflux and Barrett’s esophagus, ultimately aiming to prevent esophageal adenocarcinoma. The EndoSign ...
Mass spectrometry, known for its higher sensitivity and specificity compared to immunoassays, is particularly effective for testing molecules like Vitamin D and certain hormones where antibody-based tests struggle to differentiate between similar forms. This method allows for more precise testing. Researchers and clinicians have been investigating the use of mass spectrometry for such assays for several years. However, due to its complexity compared to standard immunoassays, mass spectrometry has largely been limited to large clinical reference laboratories and specialized testing companies that have the necessary resources and expertise to develop and conduct these tests. Now, a fully automated clinical mass spectrometry system being developed for routine lab testing could change that. Roche Diagnostics (Basel, Switzerland) is currently developing a fully automated, standardized liquid chromatography-mass spectrometry (LC-MS) solution that will seamlessly integrate into existing clinical chemistry and immunochemistry testing as part of its cobas Pro integrated solutions, as well as laboratory ...
In a recent study published in the journal BMJ Open, researchers explored the relationship between kimchi consumption and obesity in South Korea. Obesity is associated with nutritional, environmental, and lifestyle factors and is a significant risk factor for diabetes, chronic kidney disease, cardiovascular disease, and hyperlipidemia. Obesity prevalence in South Korea has increased steadily over the years. Meanwhile, the prevalence of abdominal obesity has also increased over time. Increased obesity prevalence is associated with higher medical expenditure; thus, obesity prevention remains a public health priority. In Korea, kimchi is a traditional side dish low in calories but rich in vitamins, dietary fiber, polyphenols, and lactic acid bacteria. There are concerns about kimchi as one of the major contributors to sodium intake. A 2019-20 survey revealed that daily sodium intake from kimchi was 500 mg (15% of total sodium intake). Studies have shown associations between increased sodium intake and a greater ...
Mike Hollan The shake is designed to work with regular dieters and those taking weight loss medications. Abbott announced the launch of a new brand of protein shakes named Protality. While there are plenty of protein shakes on the market, these particular shakes are designed to be used by people taking weight loss drugs. Over the past year, weigh loss or anti-obesity drugs have seen an increase in popularity and awareness. Often times, people using these medications will note a loss of appetite, which obviously goes hand-in-hand with weight loss. Unfortunately, not all of that weight loss is necessarily good. Typically, when people lose weight, they lose a combination of both muscle and fat. While fat burning is generally desired, muscle loss is not. According to Abbott’s press release, 11-50% of the weight lost by dieters can be made up of muscle. To avoid this, dieters should increase the amount ...
Time: Oct 8-10, 2024 sponsor: Informa Markets Venue:Milan International Exhibition Center City: Milan / Italy Product categories: Bulk drug: Vitamins, hormones, sulfonamides, antipyretic and analgesic drugs, tetracycline, amino acids and their derivatives, chloramphenicol, digestive system drugs, other anti-infective drugs, penicillins, aminoglycosides, lincomycin, cardiovascular system drugs, anti-parasitic diseases drugs, cephalosporins, macroliones, respiratory system drugs, central nervous system drugs, and other Western medicine raw materials. Excipients and dosage forms: excipients, flux-aids, enteric-soluble materials, antioxidants, sweeteners, permeability enhancers, preservatives, disintegrators, coating materials, surfactants, sunblocks, fragrances, filter AIDS, stabilizers, lubricants, plasticizers, solvents, flavor straighteners, colorants, clarifying agents, PH regulators. Other natural extracts: Plant extract, animal extract, traditional Chinese medicine raw materials, functional food raw materials, health products raw materials, nutrition and health products raw materials, supplements, dietary fiber, beauty cosmetics raw materials, biological product reagents: antibody, nucleic acid/protein synthesis, carrier and construction, cell biological detection, animal/plant protein/antigen/polypeptide, nucleic acid analysis, library and construction, biochemistry, standard Product/reference product, ...
Direct-to-consumer telemedicine platform Hims & Hers launched a new weight loss program Monday that offers weight loss medications, educational content and digital tracking tools. San Francisco-based Hims & Hers is a health and wellness platform that provides support for sexual health, hair, skin, primary care, mental health and other areas. The launch of the new weight loss offering comes at a time when more people are battling obesity. About 42% of U.S. adults struggle with obesity, according to the Centers for Disease Control and Prevention. Compare that to more than 20 years ago when a little over 30% struggled with obesity. The company’s new program starts with a consultation with a licensed healthcare provider from Hims & Hers. If considered appropriate, the patient will then receive a personalized treatment plan that is based on several factors, including the person’s body, health history and goals. The treatment plans have three elements. ...
In a recent study published in the journal Nutrients, researchers investigated whether a meticulously crafted meal plan for children in kindergarten aged five to six years could effectively increase their regular intake of vegetables, whole grains, and nuts. The preschool years are a time of rapid growth and development and a vital age for forming lifelong food habits. In pre-primary schools, students receive at least three meals (breakfast, lunch, and snack), which are frequently complemented by an additional snack. The relationships between foods, nutrients, and dietary patterns have significant health consequences, particularly for preventing and developing noncommunicable diseases (NCDs) such as diabetes, cardiovascular disease, and cancer. According to studies, preschoolers do not eat enough nutritional foods such as fruits, vegetables, nuts, and whole grains. About the study In the present cross-sectional study, researchers evaluated the impact of carefully designed kindergarten meals on the regular consumption of healthy foods among kindergarteners. ...
By Jamie Gumbrecht, CNN CNN — The FDA sent warnings letters to eight companies for marketing and manufacturing of unapproved eye products. Sarah Silbiger/Getty Images The US Food and Drug Administration on Monday sent warning letters to CVS, Walgreens and other companies over manufacturing and marketing of unapproved eye products the agency says could pose a risk to people who use them. The agency said the products are illegally marketed to treat conditions including conjunctivitis — pink eye — glaucoma and cataracts, and some of the warnings cited sterility issues with the products. The agency issued warning letters to CVS Health, Walgreens Boots Alliance Inc., Boiron Inc., DR Vitamin Solutions, Natural Ophthalmics Inc., OcluMed LLC, Similasan AG/Similasan USA and TRP Company Inc. Some companies have also been placed on import alert to stop products from entering the United States. “The FDA is particularly concerned that these illegally marketed, unapproved ophthalmic ...
Eight companies are finding themselves in hot water for allegedly churning out illicit eye drugs, the FDA said Tuesday. The drugs are unapproved and illegally marketed, the FDA said, which is especially risky considering that medications administered through the eye bypass some of the body’s natural defenses. The illegal therapies are purportedly used to treat diseases such as pink eye, cataracts, glaucoma and more, according to the agency’s release. The companies in the warning letter sweep are: Boiron, CVS Health, DR Vitamin Solutions, Natural Ophthalmics, OcluMed, Similasan, TRP Company and Walgreens Boots Alliance. Consumers using the illicit products should talk to a doctor, according to the FDA. The companies, for their part, must respond within 15 days of receiving the FDA’s warning letters. CVS appears to be responding quickly. Reuters reports the company said it has stopped the sale of its Pink Eye Relief Eye Drops and that customers who ...
Speculation that Stada Arzneimittel may be looking for a buyout has largely been confirmed after the company’s CEO said as much in a recent German-language news story. Responding to recent acquisition rumors, Stada CEO Peter Goldschmidt told the German Press Agency, “Whether and when STADA might be sold is solely the decision of our owners; Bain Capital and Cinven.” From the company’s view, Goldschmidt said, “our owners are in an orientation phase in which initial exploratory talks are taking place.” A Stada press representative emailed a translated version of the remarks early Tuesday along with the company’s second-quarter results. Goldschmidt added that he doesn’t expect a decision before 2024. Additionally, the company’s investors “have no pressure to sell,” the CEO pointed out. “What speaks in favor of a sale process is that it is common for financial investors to exit after five to six years,” Goldschmidt opined. Early this month, ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.